In a sobering revelation that challenges the foundation of modern cardiovascular medicine, a new study led by researchers at the Icahn School of Medicine at Mount Sinai suggests that the diagnostic tools used by millions of physicians worldwide are failing to identify nearly half of the individuals at risk for a heart attack.
The findings, published on November 21 in the Journal of the American College of Cardiology: Advances, indicate that current clinical guidelines—which rely heavily on population-based risk calculators and the presence of physical symptoms—are inherently ill-equipped to flag patients who are on the verge of a cardiac event. This gap in detection leaves a significant portion of the population vulnerable, often providing a false sense of security until it is too late.
The Mechanism of Failure: Why Standard Scores Miss the Mark
For decades, the primary gatekeepers for cardiovascular prevention have been risk scores such as the Atherosclerotic Cardiovascular Disease (ASCVD) risk score and the newer, more comprehensive PREVENT tool. During routine primary care visits, these calculators are used to estimate a patient’s 10-year risk of experiencing a heart attack or stroke. By factoring in demographic data—age, sex, and race—alongside clinical markers like blood pressure, cholesterol levels, diabetes status, and smoking history, physicians determine who should receive preventive interventions, such as statins or blood pressure medication.
However, the Mount Sinai research suggests these tools suffer from a fundamental disconnect between population-level statistics and individual-level biology.
“Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients,” says Dr. Amir Ahmadi, corresponding author and Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai. “If we had seen these patients just two days before their heart attack, nearly half would NOT have been recommended for further testing or preventive therapy guided by current risk estimate scores and guidelines.”
Chronology of a Crisis: Reconstructing the Patient Experience
To understand the scope of this diagnostic failure, the research team conducted a retrospective analysis of 474 patients. Each participant was under the age of 66, had no prior history of known coronary artery disease, and had been treated for their first-ever heart attack at either Mount Sinai Morningside or The Mount Sinai Hospital between January 2020 and July 2025.
The methodology involved a "reconstruction" of the clinical landscape. Researchers meticulously gathered demographic data, medical histories, and laboratory values for each patient. They then simulated the exact clinical encounter that would have occurred just 48 hours prior to each patient’s cardiac event. By applying the standard ASCVD and PREVENT formulas to these individuals—many of whom had been categorized as low or intermediate risk—the team was able to quantify exactly how many of these patients would have been "cleared" by the system as being at low risk for a future event.
The results were alarming:
- 45 percent of patients would not have qualified for preventive therapy or further diagnostic testing under current ASCVD-based guidelines.
- 61 percent of patients would have been categorized as low or borderline risk by the newer PREVENT tool.
Perhaps most critically, the study highlighted the limitations of relying on symptoms as a red flag. The data revealed that 60 percent of the patients reported experiencing symptoms—such as chest pain or shortness of breath—less than two days before their heart attack. This suggests that for the majority of patients, the onset of symptoms is not an "early warning sign" but rather an indicator that the disease has already reached a critical, advanced stage of progression.
Supporting Data: The Illusion of Low-Risk Status
The implications of this study are far-reaching because they dismantle the perceived safety of a "low-risk" score. In current medical practice, patients who fall into the low or borderline categories—especially those who do not report classic, acute symptoms—are often reassured by their primary care physicians and discharged without further evaluation.
This study suggests that this practice is a structural flaw. When a patient is told their risk score is low, they are essentially told that their arteries are likely clear of significant plaque buildup. However, the Mount Sinai findings indicate that "silent" atherosclerosis—plaque that has accumulated in the coronary arteries but has not yet caused symptoms—is often present even in those with low or borderline risk scores.
Dr. Anna Mueller, an internal medicine resident at Icahn Mount Sinai and the study’s first author, explains the danger of this reliance: “When we look at heart attacks and trace them backwards, most heart attacks occur in patients in the low or intermediate risk groups. This study highlights that a lower risk score, along with not having classic heart attack symptoms, is no guarantee of safety on an individual level.”
Official Responses and the Call for a Paradigm Shift
The medical community is now faced with a significant dilemma. If the current "gold standard" calculators are failing to catch the patients who need help most, what is the alternative?
Dr. Ahmadi argues that the industry needs to move away from being a "symptom-reactive" system. “This study suggests that the current approach of relying on risk scores and symptoms as primary gatekeepers for prevention is not optimal,” he states. “It may be time to fundamentally reconsider this model and move toward atherosclerosis imaging to identify the silent plaque—early atherosclerosis—before it has a chance to rupture.”
The push for early imaging, such as coronary artery calcium (CAC) scoring or coronary CT angiography (CCTA), is gaining momentum among some cardiologists. These imaging techniques can visualize the actual buildup of plaque in the arteries, providing a direct observation of disease rather than a statistical estimation of risk. By identifying "silent" atherosclerosis before it becomes unstable, clinicians could theoretically initiate aggressive preventive therapies long before a patient experiences a cardiac event.
Implications for Future Prevention and Clinical Practice
The Mount Sinai study serves as a clarion call for a revision of national and international clinical guidelines. While risk calculators are efficient for assessing large populations, the researchers emphasize that they are blunt instruments when applied to the complexities of an individual patient’s anatomy and physiology.
Key Takeaways for Clinical Care:
- Risk Scores are Not Absolute: Physicians should be cautioned against using low risk scores as a definitive reason to withhold further diagnostic investigation.
- Symptoms as a Late Indicator: The medical community must move past the idea that a lack of symptoms equates to a lack of disease. Relying on chest pain or dyspnea as an indicator of cardiac health is, in many cases, waiting for a crisis to occur.
- The Rise of Imaging: Incorporating direct imaging of the coronary arteries could bridge the gap between statistical risk and actual disease, providing a more personalized approach to cardiology.
As the authors conclude, more research is required to standardize how and when these imaging techniques should be deployed in primary care settings. The challenge lies in balancing the need for rigorous early detection with the practical realities of health care costs, resource allocation, and the potential for over-diagnosis.
However, the fundamental message of the Mount Sinai study is clear: the current "gatekeeper" model of heart attack prevention is leaking. By shifting the focus from statistical probability to the direct visualization of plaque, the medical community may finally be able to close the door on the silent, asymptomatic progression of heart disease. As technology advances and the cost of imaging continues to decrease, the transition from "calculating" risk to "seeing" disease may prove to be the most significant shift in cardiovascular care of the 21st century.
